|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's range||181.27 - 188.64|
|52-week range||90.14 - 196.00|
|Beta (3Y monthly)||2.64|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||224.17|
Does GW Pharmaceuticals PLC (GWPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
The Zacks Analyst Blog Highlights: Scott's Miracle Grow, GW Pharmaceuticals, Canopy Growth, Tilray and Aurora Cannabis
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Scotts Miracle-Gro, Ambev, International Game Technology and Ubisoft Entertainment
GW Pharmaceuticals reported surging sales last quarter, but investors ought to be aware of a lot more than that.
This drugmaker's cannabidiol formulation could become more widely used following positive phase 3 trial results in tuberous sclerosis complex.
GW Pharmaceuticals PLC shares soared 9% in premarket trade Tuesday, after Oppenheimer upgraded the stock to outperform from perform, after the company reported better-than-expected earnings along with positive results in a late-stage trial of its Epidiolex treatment. Epidilolex is the first cannabis-based drug to win approval from the U.S. Food and Drug Administration as a treatment for severe forms of childhood epilepsy. The drug is now being tested as a treatment for patients with seizures associated with tuberous sclerosis complex, or TSC. "While we await detailed data that may be shared at a medical conference, we update our probability of approval of the sNDA for TSC to 87% from 41% (filing expected in 4Q), and move to an Outperform rating and a price target of $234 (vs. $162)," Oppenheimer analyst Esther Rajavelu wrote in a note to clients. "We also like management's efforts to broaden the pipeline with open label studies of CBDV for autism spectrum disorder and Rett syndrome which may contribute to a diversified portfolio." Stifel analysts led by Paul Matteis raised their stock price target to $227 from $191 and said dinner with GW management after the earnings report "reaffirms our view that the Epidiolex launch to date, considering all of the variables that have led the product to beat consensus, is going about as well as one could've hoped." Matteis is also expecting the drug to be approved for TSC in 2019. The analyst raised his revenue forecast for Epidiolex for the second quarter to $49 million from $26 million. GW Pharma shares have gained 85% in the last 12 months, while the S&P 500 has gained 10%.
GW Pharmaceuticals PLC shares rose more than 4% in the extended session Monday after the company reported positive phase-three trial results and narrowing losses. The company reported first-quarter net losses of $50.1 million, or 14 cents a share, compared with losses of $69.5 million, or 20 cents a share, in the year-ago period. Revenue rose to $39.2 million from $3.04 million in the year-ago period. The company also reported positive results from a phase-three trial involving a drug with cannabidiol, or CBD. GW stock has gained 28% in the past year, with the S&P 500 index rising 11%.
GW Pharmaceuticals PLC said late Monday that it had a positive phase-three trial result for its Epidiolex drug. GW stock rose more than 7% in after-hours trading. Epidiolex is a drug that contains cannabidiol, or CBD, a compound found in cannabis plants. The drug is an anti-epilepsy medication and the phase-three trial was performed on 224 patients in six countries. GW said it was the fifth consecutive positive trial for Epidiolex. GW stock has gained 28% in the past year, as the S&P 500 index rose 11%.
Following the U.S.-commercial launch of Epidolex last November, GW Pharmaceuticals (GWPH) continues to see an uptick from the same.
In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $165.99, marking a -1.96% move from the previous day.
Cannabis Updates: Price Action, Ratings, and MoreCannabis spaceThe cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively, while the
GW Pharmaceuticals PLC (GWPH) closed at $162.45 in the latest trading session, marking a +0.88% move from the prior day.
Cannabis stocks were mostly lower Tuesday, as investors took a breather after Monday’s gains to lock in profits and await the next developments in the sector.